Phase i studies with baker's antifol (baf) (nsc 139105)

Victorio Rodriguez; Jeffrey Gottlieb; Michael A. Burgess; Robert Livingston; Warren Wheeler; Gary Spitzer; Gerald P. Bodey; George R. Blumenschein; Emil J. Freireich

doi:10.1002/1097-0142(197608)38:2<690::AID-CNCR2820380212>3.0.CO;2-X

Phase i studies with baker's antifol (baf) (nsc 139105)

Victorio Rodriguez, Jeffrey Gottlieb, Michael A. Burgess, Robert Livingston, Warren Wheeler, Gary Spitzer, Gerald P. Bodey, George R. Blumenschein, Emil J. Freireich

Cancer Center

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Phase I studies were conducted in 58 adult cancer patients with Baker's Antifol (BAF), a new active‐site directed inhibitor of dihydrofolate reductase. Dose escalation ranged from 10 to 250 mg/m²/day × 5 days and courses of treatment were repeated every 2‐3 weeks. Biologic effects were observed mostly at doses > 100 mg/m²/day × 5 days. The patients developed myelosuppression during 19% of the trials. Other types of toxicity were dermatitis in 12 to 30% and stomatitis in 7 to 38% of the trials. Toxicity was directly related to the impairment of the patient's liver function. Two partial responses (in a patient with adenocarcinoma of the lung and a patient with transitional cell carcinoma of the bladder) occurred. BAF is an active new chemotherapeutic agent which deserves further clinical trials in patients with various malignancies.

Original language	English (US)
Pages (from-to)	690-694
Number of pages	5
Journal	Cancer
Volume	38
Issue number	2
DOIs	https://doi.org/10.1002/1097-0142(197608)38:2<690::AID-CNCR2820380212>3.0.CO;2-X
State	Published - Aug 1976

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197608)38:2<690::AID-CNCR2820380212>3.0.CO;2-X

Cite this

@article{3c0abb30b4634d929eb820ab83f9ee80,

title = "Phase i studies with baker's antifol (baf) (nsc 139105)",

abstract = "Phase I studies were conducted in 58 adult cancer patients with Baker's Antifol (BAF), a new active‐site directed inhibitor of dihydrofolate reductase. Dose escalation ranged from 10 to 250 mg/m2/day × 5 days and courses of treatment were repeated every 2‐3 weeks. Biologic effects were observed mostly at doses > 100 mg/m2/day × 5 days. The patients developed myelosuppression during 19% of the trials. Other types of toxicity were dermatitis in 12 to 30% and stomatitis in 7 to 38% of the trials. Toxicity was directly related to the impairment of the patient's liver function. Two partial responses (in a patient with adenocarcinoma of the lung and a patient with transitional cell carcinoma of the bladder) occurred. BAF is an active new chemotherapeutic agent which deserves further clinical trials in patients with various malignancies.",

author = "Victorio Rodriguez and Jeffrey Gottlieb and Burgess, {Michael A.} and Robert Livingston and Warren Wheeler and Gary Spitzer and Bodey, {Gerald P.} and Blumenschein, {George R.} and Freireich, {Emil J.}",

year = "1976",

month = aug,

doi = "10.1002/1097-0142(197608)38:2<690::AID-CNCR2820380212>3.0.CO;2-X",

language = "English (US)",

volume = "38",

pages = "690--694",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Phase i studies with baker's antifol (baf) (nsc 139105)

AU - Rodriguez, Victorio

AU - Gottlieb, Jeffrey

AU - Burgess, Michael A.

AU - Livingston, Robert

AU - Wheeler, Warren

AU - Spitzer, Gary

AU - Bodey, Gerald P.

AU - Blumenschein, George R.

AU - Freireich, Emil J.

PY - 1976/8

Y1 - 1976/8

N2 - Phase I studies were conducted in 58 adult cancer patients with Baker's Antifol (BAF), a new active‐site directed inhibitor of dihydrofolate reductase. Dose escalation ranged from 10 to 250 mg/m2/day × 5 days and courses of treatment were repeated every 2‐3 weeks. Biologic effects were observed mostly at doses > 100 mg/m2/day × 5 days. The patients developed myelosuppression during 19% of the trials. Other types of toxicity were dermatitis in 12 to 30% and stomatitis in 7 to 38% of the trials. Toxicity was directly related to the impairment of the patient's liver function. Two partial responses (in a patient with adenocarcinoma of the lung and a patient with transitional cell carcinoma of the bladder) occurred. BAF is an active new chemotherapeutic agent which deserves further clinical trials in patients with various malignancies.

AB - Phase I studies were conducted in 58 adult cancer patients with Baker's Antifol (BAF), a new active‐site directed inhibitor of dihydrofolate reductase. Dose escalation ranged from 10 to 250 mg/m2/day × 5 days and courses of treatment were repeated every 2‐3 weeks. Biologic effects were observed mostly at doses > 100 mg/m2/day × 5 days. The patients developed myelosuppression during 19% of the trials. Other types of toxicity were dermatitis in 12 to 30% and stomatitis in 7 to 38% of the trials. Toxicity was directly related to the impairment of the patient's liver function. Two partial responses (in a patient with adenocarcinoma of the lung and a patient with transitional cell carcinoma of the bladder) occurred. BAF is an active new chemotherapeutic agent which deserves further clinical trials in patients with various malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0017130247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017130247&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197608)38:2<690::AID-CNCR2820380212>3.0.CO;2-X

DO - 10.1002/1097-0142(197608)38:2<690::AID-CNCR2820380212>3.0.CO;2-X

M3 - Article

C2 - 974989

AN - SCOPUS:0017130247

SN - 0008-543X

VL - 38

SP - 690

EP - 694

JO - Cancer

JF - Cancer

IS - 2

ER -

Phase i studies with baker's antifol (baf) (nsc 139105)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this